Alteogen introduced on Dec. 26 that it has signed an possibility contract with a worldwide pharmaceutical firm for the know-how switch of its subcutaneous injection (SC) formulation platform ALT-B4.
Alteogen determined to not disclose the corporate identify and product identify because of the aggressive panorama of the companion firm’s merchandise. Beneath the contract, the companion firm will obtain knowledge for making use of ALT-B4 to its presently marketed product and pay possibility charges to Alteogen.
The ultimate know-how switch contract is scheduled to be concluded inside subsequent yr relying on growth progress. An Alteogen official defined, “This can be a separate contract from the present case that was within the last levels of know-how switch contract discussions.”
ALT-B4 is a know-how that allows large-volume subcutaneous injections by briefly breaking down pores and skin and hyaluronic acid. It was developed via Alteogen’s proprietary platform know-how Hybrozyme. To this point, Alteogen has transferred its platform know-how to a complete of 6 international pharmaceutical firms together with Merck & Co. (MSD), AstraZeneca, Sandoz, and Daiichi Sankyo.
